StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) company profile

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30397% above fair value
$27.33+0.18 (+0.66%)

Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –

About Arcutis Biotherapeutics

Pharmaceutical Preparations, SIC 2834

This commercial-stage biopharmaceutical enterprise develops and markets treatments for immune-mediated skin disorders. The business concentrates on dermatological therapies, offering topical roflumilast formulations under the ZORYVE brand in cream and foam formats. These commercialized products are prescribed for conditions including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis across various adult and pediatric age groups. In addition to commercial assets, development efforts encompass an experimental biologic fusion protein, ARQ-234, aimed at inflammatory conditions. Target prescribers and healthcare customers primarily include dermatologists, pediatricians, and primary care physicians caring for patients with chronic inflammatory skin diseases.

Operations and commercial distribution are established in the United States and Canada, supplemented by international licensing and collaboration partnerships covering Japan, Greater China, and Southeast Asia. The provided filing text does not disclose the enterprise's corporate headquarters location or physical facility metrics.

Summary of the business section of Arcutis Biotherapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Arcutis Biotherapeutics, Inc.
Headquarters
Westlake Village, CA
Address
3027 Townsgate Road, Suite 300 91361
Phone
(805) 418-5006
Employees
354, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Los Angeles, California

Stock & identifiers

Ticker
ARQT
Exchange
Nasdaq
IPO date
Jan 31, 2020
Shares outstanding
126M, Jul 31, 2026
Public float
$1.53B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1787306
CUSIP
03969K108
ISIN
US03969K1088
FIGI
BBG00QN8K4M4
Share class FIGI
BBG00QN8K4P1
EIN
81-2974255

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Todd WatanabeSee Remarks, Director895,140
Patrick BurnettEVP, Chief Medical Officer116,649
Robert LisickiEVP, Chief Commercial Officer55,000
Masaru MatsudaEVP, Chief Legal Officer111,289
Latha VairavanSVP Chief Financial Officer85,978
Larry Todd EdwardsSee Remarks175,178
David Joseph TopperChief Financial Officer182,774
Robert A. ScottDirector20,342
Howard G. WelgusDirector60,198
Terrie CurranDirector23,526
Christopher PeetzDirector191,815
Sue-Jean LinDirector27,567
Patrick J. HeronDirector59,661
Keith R. LeonardDirector29,651
Halley E. GilbertDirector27,901
Neha KrishnamohanDirector27,901
Amit MunshiDirector9,799
Bhaskar ChaudhuriDirector917,807

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.22M$20.35M$2.41M$103$120
FY2024$3.69M$11.21M$2.73M$50$91
FY2023$4.94M-$1.16M$1.62M$11$92
FY2022$4.58M$2.42M$2.31M$53$89
FY2021$4.82M$441.90K$3.07M$74$99
FY2020$2.75M$16.77M$4.06M$129$133

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Todd Franklin Watanabe
President and Chief Executive Officer
$713.33K$2.07M$3.85M$579.58K$14.00K$7.22M+96%
Latha Vairavan
Chief Financial Officer
$419.49K$440.41K$839.46K$213.40K$12.02K$1.92M–
Patrick E. Burnett, M.D., Ph.D.
Chief Medical Officer
$535.00K$752.95K$1.38M$334.38K$14.00K$3.02M+20%
L. Todd Edwards
Chief Commercial Officer
$535.00K$752.95K$1.38M$334.38K$27.83K$3.03M+54%
Masaru Matsuda, J.D.
Chief Legal Officer
$495.17K$465.46K$865.04K$278.53K$14.00K$2.12M+22%
David Topper
Former Chief Financial Officer
$196.46K$465.46K$865.04K–$419.77K$1.95M-63%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 31, 2020
Offer price
$17.00
Securities offered
9,375,000
Gross proceeds
$159.38M
Exchange
Nasdaq
First trading day
Jan 31, 2020
First-day close
$21.80+28.2%
Lock-up ends (est.)
Jul 29, 2020

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 354 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 31, 2020IPOInitial public offering priced (424B4 prospectus)
Jan 21, 2020ListingRegistration of securities on an exchange (Form 8-A)
Sep 9, 2019Name changeName changed from Arcutis, Inc. to Arcutis Biotherapeutics, Inc.

See a number that looks wrong?